Autism Diagnostic Observation Schedule (ADOS-2) Administration Training

When May 11, 2017 08:30 AM to
May 12, 2017 04:30 PM
Where Morehead Conference Center 111 East First Street Morehead, KY 40351
Contact Name
Contact Phone (502)852-2467
Add event to calendarvCal

Registration begins at 8:00 AM Central Time


The Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) is a semi-structured, standardized measure of communication, social interaction, play/imagination, and restricted and/or repetitive behaviors published by Western Psychological Services. The ADOS-2 is often referred to as the “gold standard” measure of observational assessment for autism spectrum disorder.

Individuals who can administer the ADOS-2 are clinical and school psychologists, psychiatrists, developmental pediatrician, occupational therapists, and speech pathologists that have prior education, training, and experience in conducting individually administered test batteries and, training by an independent trainer or the test publisher is required.


Pending Continuing Education

Continuing Education Approval is being requested from each of the professional organizations listed below:

Kentucky Licensure Board of Speech Language Pathology

Kentucky Licensure Board of Occupational Therapy

Kentucky Board of Psychology



Rachel Hundley, Ph.D.

Assistant Professor of Pediatrics, Division of Developmental Medicine; Assistant Professor of Psychiatry; Psychologist, Vanderbilt Kennedy Center Learning Assessment Clinic

As a trainer for the Autism Diagnostic Observation Schedule, she has taught this measure nationally and internationally. In clinical settings, she has mentored postdoctoral fellows in psychology as well as psychology graduate and undergraduate students. Her previous research has primarily focused on social development and developmental disabilities, including autism and genetic disorders. At Vanderbilt, she is contributing to a study assessing the cognitive, behavioral, and neural components of Angelman syndrome, Rett syndrome, and MeCP2 duplication, and to a study of sleep intervention for children with ASD. She is part of the Autism Treatment Network (ATN), and she represents Vanderbilt on the Behavioral Sciences Committee for the ATN. She will soon begin working with colleagues at Vanderbilt and in Boston to examine the efficacy of a new medicine designed to address neurodevelopment and abnormal movements in Angelman syndrome.

More information about this event…